Skip to main content

Table 1 Basic demographic and clinical data distribution of the studied patients

From: Evaluation of the efficacy of pirfenidone in progressive chronic hypersensitivity pneumonitis

  Group 1 Group 2 t/X2 P
Age(year) 48.65 ± 8.59 44.55 ± 7.46 1.611 0.115
BMI (kg/m2) 28.98 ± 4.85 29.13 ± 3.99 0.784 0.485
Duration (year) 1.85 ± 0.62 1.77 ± 0.57 − 0.851 0.412
Sex Female N 6 7   
% 30.0 35.0   
Male N 14 13 0.114 0.73
% 70.0 65.0   
Comorbid No N 15 17   
% 75.0 85.0   
DM N 2 2 1.12 0.57
% 10.0 10.0   
HTN N 3 1   
% 15.0 5.0   
Total N 20 20   
% 100.0% 100.0   
  1. BMI body mass index, DM diabetes mellitus, HTN hypertension